The authors performed a comprehensive search of several databases to identify preclinical and clinical studies using autologous CD34+ cell therapy for the treatment of CVD, including heart failures, such as dilated cardiomyopathy and ischemic cardiomyopathy, acute myocardial infarction (AMI), and refractory angina. Here, CD34 is linked to dilated cardiomyopathy.